IGFBP-rP1 Is a Potential Therapeutic Target in Androgenic Alopecia
February 2024
in “
Experimental Dermatology
”
Studysummary In this study, researchers found that IGFBP‐rP1 levels were lower in individuals with androgenic alopecia compared to healthy controls, and subcutaneous injection of IGFBP‐rP1 showed potential in slowing hair loss progression in a mouse model by affecting the hair cycle transition.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on onlinelibrary.wiley.com →